INSM
Insmed Incorporated
NASDAQ · USHealthcareBiotechnology
$107.02-1.20%
Price as of Jul 20, 2026
INSM profitability
Insmed Incorporated profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 81.6%
- EBITDA margin
- -131.9%
- EBIT margin
- -137.7%
- Net margin
- -144.4%
- Free cash flow margin
- -116.1%
Returns
- Return on equity
- -167.9%
- Return on assets
- -57.0%
- Return on invested capital
- -77.7%
- Asset turnover
- 0.38x
Cash efficiency
- Cash from operations
- -$895.7M
- Cash per share
- $5.64
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.